Rallybio (RLYB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating on the stock and has a $7.00 price target.
Jonathan Wolleben’s rating is based on several promising developments in Rallybio’s clinical pipeline and financial stability. The company has recently dosed the first pregnant woman in its Phase 2 trial of RYLB212, which is a significant milestone as it aims to demonstrate the drug’s safety and pharmacokinetics in pregnant women. This trial targets a condition known as FNAIT, with a substantial market potential given the estimated 30,000 at-risk pregnancies annually in the U.S. and EU.
Additionally, Rallybio’s financial position is strong, with $66 million in cash, providing a runway into the second half of 2026. The company is also advancing its C5 inhibitor RLYB116, which could offer advantages over existing treatments in several indications. These factors, combined with the potential blockbuster status of RYLB212, underpin Wolleben’s Buy rating for the stock.